Reference

Changes in rat cardiac and skeletal muscle creatine kinase activity during tubocurarine, arduane and myorelaxin induced myorelaxation

Changes in rat cardiac and skeletal muscle creatine kinase activity during tubocurarine, arduane and myorelaxin induced myorelaxation. Mozgovaya, E. N.; Krapivina, O. V. (Med. Inst., Dnepropetrovsk, USSR). Ukr. Biokhim. Zh., 56(5), 555-8 (Russian) 1984. CODEN: UBZHD4. ISSN: 0201-8470. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Tubocurarine [57-94-3] (0.5 mg/kg, i.p.) and arduan [52212-02-9] (0.3 mg/kg, i.p.) both muscle relaxants of the nondepolarizing type, decreased creatine kinase [9001-15-4] activity in myocardial exts. by ~2- and 3-fold, resp., but had no effect on the enzyme in skeletal muscle. Myorelaxin [55-94-7], a depolarizing muscle relaxant, had no effect on the enzyme in either the myocardium or skeletal muscle.

Protein-binding of pipecuronium bromide (Arduan) in human plasma

Protein-binding of pipecuronium bromide (Arduan) in human plasma. Szeleczky, G.; Ronai-Lukacs, S.; Vereczkey, L. (Dep. Pharmacokinet. Drug Metab., Chem. Works Gedeon Richter Ltd., Budapest H-1475, Hung.). Stud. Org. Chem. (Amsterdam), 18(Bio-Org. Heterocycl.), 251-4 (English) 1984. CODEN: SOCHDQ. ISSN: 0165-3253. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) 3H-labeled pipecuronium bromide (I) [52212-02-9] did not bind to human plasma proteins at concns. of 0.26-1290 ng I/mL; the free fraction of I was 98.2%. I decompn. during filtration was ruled out. The lack of any binding of I to plasma proteins may explain the extremely low doses of I required for muscle relaxation.